TY - JOUR
T1 - Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers
AU - Houlle, Solene
AU - Charbonnier, Françoise
AU - Houivet, Estelle
AU - Tinat, Julie
AU - Buisine, Marie Pierre
AU - Caron, Olivier
AU - Benichou, Jacques
AU - Baert-Desurmont, Stéphanie
AU - Frebourg, Thierry
N1 - Funding Information:
We thank our colleagues who referred to us to Lynch patients. This study was supported by the French Canceropole Nord-Ouest and the French National Cancer Institute (INCa). We are grateful to Mario Tosi for critical review of the manuscript.
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Several studies have reported that, in Lynch syndrome resulting from mutations of the mismatch repair (MMR) genes, a CA repeat 17 within the IGF1 promoter, SNPs within the xenobiotic metabolizing enzyme gene CYP1A1 and SNPs on 8q23.3 and 11q23.1 modify colorectal cancer (CRC) risk in MMR mutation carriers. We analysed the impact of these polymorphisms on CRC risk in 748 French MMR mutation carriers derived from 359 families. We also analysed the effect of the Novel 1 SNP (18q21), which has recently been shown to increase CRC risk in the general population. We observed a significant difference in the CRC-free survival time between males and females, between MSH2 and MSH6 mutation carriers and between MLH1 and MSH6, indicating that this series is representative of Lynch syndrome. In contrast, the univariate log-rank test, as well as multivariate Cox model analysis controlling for familial aggregation and mutated MMR gene, year of birth and gender showed that the polymorphic alleles tested were not associated with a significant CRC risk increase, neither on the entire sample nor among males and females. This discrepancy with previous reports might be explained both by the genetic heterogeneity between the different populations analysed and the allelic heterogeneity of the MMR mutations. We conclude that genotyping of these polymorphisms is not useful to evaluate CRC risk in MMR mutation carriers and to optimize their clinical follow-up.
AB - Several studies have reported that, in Lynch syndrome resulting from mutations of the mismatch repair (MMR) genes, a CA repeat 17 within the IGF1 promoter, SNPs within the xenobiotic metabolizing enzyme gene CYP1A1 and SNPs on 8q23.3 and 11q23.1 modify colorectal cancer (CRC) risk in MMR mutation carriers. We analysed the impact of these polymorphisms on CRC risk in 748 French MMR mutation carriers derived from 359 families. We also analysed the effect of the Novel 1 SNP (18q21), which has recently been shown to increase CRC risk in the general population. We observed a significant difference in the CRC-free survival time between males and females, between MSH2 and MSH6 mutation carriers and between MLH1 and MSH6, indicating that this series is representative of Lynch syndrome. In contrast, the univariate log-rank test, as well as multivariate Cox model analysis controlling for familial aggregation and mutated MMR gene, year of birth and gender showed that the polymorphic alleles tested were not associated with a significant CRC risk increase, neither on the entire sample nor among males and females. This discrepancy with previous reports might be explained both by the genetic heterogeneity between the different populations analysed and the allelic heterogeneity of the MMR mutations. We conclude that genotyping of these polymorphisms is not useful to evaluate CRC risk in MMR mutation carriers and to optimize their clinical follow-up.
UR - http://www.scopus.com/inward/record.url?scp=79960647449&partnerID=8YFLogxK
U2 - 10.1038/ejhg.2011.44
DO - 10.1038/ejhg.2011.44
M3 - Article
C2 - 21407259
AN - SCOPUS:79960647449
SN - 1018-4813
VL - 19
SP - 887
EP - 892
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 8
ER -